Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.
about
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature reviewRole of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvementAutoantibody profile in rheumatoid arthritis during long-term infliximab treatmentA combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritisAnti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature reviewAssessment of anti-cyclic citrullinated peptide in psoriatic arthritis.Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA).Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients.Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Insights from populations at risk for the future development of classified rheumatoid arthritisAdalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis.Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvementDiagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritisSmoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritisAutoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis.Arthritis of the large joints - in particular, the knee - at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis.Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis.The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis RegisterAntibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial.The association of anti-CCP antibodies with disease activity in rheumatoid arthritisNovel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes.Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis.The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis.Rheumatoid factors: clinical applications.Autoimmunity to citrullinated type II collagen in rheumatoid arthritisAnti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review.Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection.The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosis.Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
P2860
Q24675281-DC0D5195-3496-4A9B-8112-E325E3734256Q24793557-B968ECF8-E728-41D7-AD68-E440DBECA7FFQ24800888-AFBC103C-6208-4A9D-890E-3BFA7D17034DQ24805387-301A8097-4712-43F5-A4F4-C9D2D4B89DF8Q27001098-24338719-236D-46B4-8B80-AD2200C16198Q33419722-DB39E01C-762E-4C21-ADB2-6B8A8BBB6DD8Q33770863-BD955DB6-8065-481F-8943-4389E42C1943Q33923250-E8C89C8C-480F-4BF1-AB92-F8D24136845BQ34460622-E33BC72B-33C6-4877-ACBA-8473D5CD2DB9Q34559803-08E59302-5E06-47B5-8AF7-3F8C42D616E2Q34604615-5F86ECEF-60C5-4B99-B494-0D57F2EABFE5Q34896439-0FBA92CF-9959-4104-981A-E635D3BFBBB7Q34897056-08C059BC-DF42-4A55-8AA2-0F380DF19DB5Q35553375-370D689D-57B1-4FFA-8677-E66F0F2E422AQ35554481-C2FD6C2D-B632-464E-BC2D-77062FEB5CD8Q35556014-EE4C8B53-4E2E-40D5-89DA-49D47C386D98Q35636886-7F7F71BA-B942-446C-B65B-5DF3A363F68CQ35760039-49EDD726-FDA9-45C0-AD55-80B22AE07BA4Q35934700-B319A0C9-E47D-4D68-A876-74A4B505BCB9Q35953226-1B9B8F15-2B2C-47F7-9B85-7948B6A735FCQ35973747-E1B0196B-21FF-42E5-A3FE-3BCAB8503EE0Q36213507-8402D856-D346-43BC-83E0-65500C613DA4Q36395509-62553BD2-E161-4D06-86D5-52FF02EE4441Q36732099-D1BC785C-BFE2-4A6F-809B-7AE4B3F5A55CQ36740473-DB4927ED-2C76-4450-9151-721AE6D6481BQ36773674-467C55BB-6120-4A43-9A54-7FE221F4C712Q36805269-A99AAFD1-804C-46AC-8E7E-E729CE33147AQ37018598-21664B0C-9613-4808-81C5-0943F1B7E40BQ37106351-2BF52723-6D50-4E60-836B-30C7CE0ECB6AQ37280952-F3C91A84-A2A5-40A4-A055-BBDEDD85B263Q37283829-0D73E617-2C8C-4103-898E-4D1E0CFE709EQ37353700-53618949-05BB-4447-AA2F-2740F03ED401Q37428764-E775705A-6A7A-4D31-B4BD-8CDDE257DF15Q37624583-C5411121-E4AA-425A-8C2C-C4295C56F199Q37771781-F6163E49-CB76-4490-923A-468B8DDCF104Q38896045-87F872FB-476E-430A-BAD2-6A48E6A7B440Q39029106-D385A798-D9B9-4132-91EE-9A1CFFCF86E1Q39091666-B65383A7-7DCA-4FAE-8BF0-EE2259F728E2Q39920872-BBFA2DF4-6274-4C6D-A690-44DA37785CA4Q41027570-B2B2AF19-27E5-4036-8F13-14A56AB08F78
P2860
Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@en
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@nl
type
label
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@en
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@nl
prefLabel
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@en
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@nl
P2093
P356
P1433
P1476
Anti-cyclic citrullinated pept ...... nosis of rheumatoid arthritis.
@en
P2093
P304
P356
10.1093/RHEUMATOLOGY/KEG184
P577
2003-05-01T00:00:00Z